Axsome Therapeutics, Inc. (AXSM) is a pioneering biopharmaceutical company focused on developing and delivering innovative therapies in the healthcare space, primarily targeted towards central nervous system (CNS) disorders.
Founded in 2012 and headquartered in New York City, Axsome Therapeutics operates with the mission to create distinctive therapies that improve quality of life for patients grappling with limited treatment options. These include individuals struggling with conditions such as major depressive disorder, Alzheimer's disease, treatment-resistant depression, migraine, and agitation associated with Alzheimer's disease.
The company lays heavy emphasis on the development of a robust and diversified product line-up that encompasses novel medicines with technology-driven delivery systems. To bring their vision to life, Axsome Therapeutics is backed by a team of highly skilled scientists and industry professionals who are committed to a strategic approach in research, development, and commercialization of potentially life-changing pharmaceuticals.
As of now, Axsome Therapeutics has several leading products in various stages of clinical development. Two of its leading CNS product candidates are AXS-05 and AXS-07. AXS-05 is being developed for major depressive disorder and treatment-resistant depression, among others, and AXS-07 is being developed for treating acute migraine. Both these drugs have exhibited strong potential and encouraging results in their respective clinical trials.
In addition to these, the company has a rich pipeline of promising product candidates like AXS-12 and AXS-14. AXS-12 is targeted to treat narcolepsy, and AXS-14 is for chronic pain associated with osteoarthritis of the knee.
The successful advancements and potential of its leading products have significantly contributed to Axsome Therapuetics' impressive performance in the stock market. The company is publically traded on the NASDAQ under the symbol “AXSM”.
Though the company is relatively young, it is aggressively moving forward in its pursuit to deliver next-generation CNS medicines. Axsome Therapeutics' relentless dedication, emphasis on innovation, and the high potential of its clinical candidates are making it a company to watch in the biopharmaceutical arena.
Lastly, Axsome is more than just a corporation; it’s a team devotedly pushing the boundaries of CNS treatments. The company's work has the potential to significantly better the lives of patients and families affected by these life-altering disorders and diseases. In doing so, Axsome Therapeutics is not only advancing medical science but making a meaningful difference in the global community.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Morgan Stanley analyst Sean Laaman maintained an "Equal-Weight" rating for Axsome Therapeutics (AXSM) but lowered its price target to $247 from $251. This adjustment reflects a cautious outlook amidst a competitive biotechnology landscape. Despite strong momentum and interest from institutional investors, the company's low profitability, financial strength, and high forward P/E ratio suggest potential concerns for investors.
Truist Securities has initiated coverage on Axsome Therapeutics, Inc. with a "Buy" rating. The firm has set a new target price of $285 for the company's stock, which represents a significant increase from the previous target of $200. This upgrade suggests a strong positive outlook from Truist Securities regarding Axsome Therapeutics' future performance.
Axsome Therapeutics (AXSM) is a biotechnology company focused on CNS disorders, showing a promising 37% upside potential with an average target price of $285.42 and 20 buy ratings from analysts. Despite current negative EPS and free cash flow due to reinvestment, its robust pipeline and strategic collaborations, like with Duke University for smoking cessation research, position it as a compelling opportunity for growth-oriented investors in the biotech sector. The company's innovative product lineup, including Auvelity and Sunosi, addresses significant unmet medical needs.
Axsome Therapeutics (AXSM) recently presented new data at Psych Congress 2026 for major depressive disorder and Alzheimer’s disease agitation, drawing attention to its pipeline. Despite short-term stock fluctuations, long-term performance has been strong. The company is currently trading at a significant discount to its estimated intrinsic value and analyst targets, raising questions about whether it is mispriced or if the valuation reflects execution and earnings risk.
Axsome Therapeutics (NASDAQ: AXSM) presented at the H.C. Wainwright 28th Annual Global Investment Conference, detailing strong growth for its commercial products, especially Auvelity, which is a major driver of revenue. The company expanded its sales force significantly to support the new Alzheimer’s disease agitation indication for Auvelity and highlighted the continued growth of Sunosi and SYMBRAVO. Axsome also discussed its robust pipeline with several late-stage programs and a strong financial position, approaching cash-flow positivity.